Baseline Participant Characteristics
lung cancer, bronchiectasis, asthma, COPD
BRONCHIECTASIS, TUBERCULOSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, COPD, LUNG CANCER, S; HEMOGLOBIN, ASTHMA, INTERSTITIAL LUNG DISEASE, PULMONARY HYPERTENSION
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); COPD, chronic obstructive pulmonary disease; FEU, fibrinogen equivalent units; IL-6, interleukin 6; ULN, upper limit of normal.SI conversion factors: To convert D-dimer to nanomoles per liter, multiply by 5.476; C-reactive protein to milligrams per liter, multiply by 10; creatinine to micromoles per liter, multiply by 88.4; hemoglobin to grams per liter, multiply by 10; lymphocytes to ×10Data are presented as number (percentage) or number/total number (percentage) of patients unless otherwise indicated.This trial collected self-reported race and ethnicity data from either the participants or their surrogates via fixed categories appropriate to their region.Not further specified.Data were systematically collected for each patient using predefined questions in the electronic case report form. If this information was not available and/or not reported in the hospital records, the site personnel ticked either “not reported” or “information not available” (as appropriate).Includes home oxygen therapy, asthma, COPD, bronchiectasis, interstitial lung disease, lung cancer, pulmonary hypertension, and tuberculosis.Each site provided the local reference ranges for the assays: C-reactive protein, creatinine, hemoglobin, lymphocyte count, and platelet count. The reference ranges differed per site.Initial adherence to protocol-assigned P2Y12 inhibitor was high, with 472 of 479 participants (98.5%) receiving at least 1 dose of a P2Y12 inhibitor, either ticagrelor (372 [78.8%]) or clopidogrel (100 [21.2%]) (eTable 2 in 